RxDoctor Payments Data

Jodi Wojciechowski

Family · Saginaw, MINPI 1720318553

Payments from drug & device makers

$2,221in general payments, 2019–2025

Across 96 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$696
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$274
  • Bristol Myers Squibb$184
  • Johnson & Johnson$176
  • E.r. Squibb & Sons, L.L.C.$130
  • AstraZeneca$91
  • plus $672 from 16 others

What the payments were for

  • Food & beverage$2,20799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,221 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$18,034
Medicare patients
205
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$111,606
LinzessLinaclotide49$41,803
XifaxanRifaximin12$32,452
CreonLipase/Protease/Amylase12$29,479
TrulancePlecanatide29$24,500
Mesalamine19$7,894
Lubiprostone29$6,170
MovantikNaloxegol Oxalate11$4,470
Sucralfate26$2,683
Pantoprazole Sodium90$1,166
Omeprazole48$659
Albuterol Sulfate HfaAlbuterol Sulfate14$358
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$277
Dicyclomine Hcl14$220
Cephalexin23$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$30$111,60612 claims
AbbVieLinzess, Creon$696$71,28261 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$274$56,95241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →